---
title: "Celcuity plunges nearly 17% as breast cancer drug launch delayed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292779112.md"
description: "Celcuity plunged 17% to $92.68. HC Wainwright raised price target to $155, but breast cancer drug delay dragged shares."
datetime: "2026-07-15T13:52:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292779112.md)
  - [en](https://longbridge.com/en/news/292779112.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292779112.md)
---

# Celcuity plunges nearly 17% as breast cancer drug launch delayed

Celcuity(CELC.US) 盘中跌**16.54%**，现报**92.68**美元。

消息面上，HC Wainwright 将 Celcuity 目标价上调至 155 美元。然而， Reuters 报道称 Celcuity 乳腺癌药物发布延迟，影响了其首个 FDA 批准的利好效应，对股价形成拖累。

### Related Stocks

- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)

## Related News & Research

- [CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/294642754.md)
- [11:22 ETCELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm](https://longbridge.com/en/news/294532569.md)
- [Celcuity says NCCN guidelines add newly FDA-approved REVTORPYK for advanced HR+/HER2- breast cancer](https://longbridge.com/en/news/294366586.md)
- [NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm](https://longbridge.com/en/news/294126837.md)
- [BUZZ-Celcuity rises after FDA approval for breast cancer drug](https://longbridge.com/en/news/292667938.md)